Pharmicell Co., Ltd.
Pharmicell Co., Ltd. (KRX: 005690) is trading at ₩12,860.00, about ₹928 at today's KRW/INR rate, as of 8 Oct 2026, 2:30 AM ET, down 1.23% today. Pharmicell is not currently available to trade on Paasa; this page shows its price, statistics and the Indian tax treatment for information.
Quote
Today's low
₩12,720.00
Today's high
₩13,100.00
52 week low
₩8,140.00
52 week high
₩21,150.00
005690 opened at ₩13,100.00, closed previously at ₩13,020.00, and has traded between ₩8,140.00 and ₩21,150.00 over the past 52 weeks.
About
Headquartered in Seoul, South Korea, Pharmicell Co., Ltd. is a biopharmaceutical company established in 2002, actively developing and marketing stem cell treatments across South Korea and globally. The firm operates through two primary segments: Biopharmaceutical Business and Biochemical Business. Its flagship approved product, Cellgram_AMI, leverages a patient's own bone marrow-derived mesenchymal stem cells to enhance heart pumping capacity (ejection fraction) in individuals who have suffered acute myocardial infarction and subsequently undergone coronary angioplasty. Beyond this, Pharmicell is actively progressing several pipeline candidates, including Cellgram_LC for liver ailments, Cellgram_ED targeting impotence, Cellgram_DC for cancer treatment, and Hearticellgram_AM for various cardiac conditions. In its Biochemical division, the company produces crucial intermediates for pharmaceutical raw materials, such as nucleosides, mPEGs, and HDP-tosylate, alongside manufacturing specialized industrial materials like low dielectric constant substances and eco-friendly flame retardants. Furthermore, Pharmicell operates "Twelve," a dedicated stem cell bank, and formulates cosmetics utilizing stem cell culture media.
Key statistics
Avg. volume
977.81K
Market cap
₩771.65B
P/E Ratio
16.58
Price-to-sales ratio
5.68
Enterprise value
₩857.78B
Free cash flow yield
3.85%
Debt-to-equity ratio
0.18
Return on equity
32.56%
ROIC
23.45%
Beta
0.62
Dividend yield
0.39%
Last dividend
₩50.00
Financial overview
Revenue
₩114.06B
Earnings per share
₩671.97
Free cash flow
₩33.60B
Net profit margin
34.26%
Gross margin
44.08%
EBITDA
₩36.81B
Revenue growth
75.88%
Pharmicell for Indian investors
Pharmicell is listed on the Korea Exchange. It is not currently available to trade on Paasa; the figures on this page are for information, and the tax notes below apply to Indian residents who hold it.
Taxes on Pharmicell for Indian residents
Trading and limits
- Trading hours
- 9:00 am – 3:30 pm KST
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- Slab rateDividends are taxed at your slab rate in India. Pharmicell’s current yield is 0.39%.Dividend tax explained
FAQs
Can I buy Pharmicell on Paasa?
Pharmicell (005690) has been listed on the Korea Exchange since 2000, in the Biotechnology industry. Pharmicell is not currently available to trade on Paasa; the figures on this page are for information. Indian residents who hold it through another broker still declare it under the rules below.
How much does one Pharmicell share cost in rupees?
One Pharmicell share is ₩12,860.00 — about ₹928 at a KRW/INR rate of 0.0722 on 8 Oct 2026. Both the Pharmicell price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for investing abroad from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability.
How are gains on Pharmicell shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the KRW/INR rate on the purchase and the sale date, so the rupee move counts alongside the Pharmicell price.
Does Pharmicell pay a dividend, and how is it taxed in India?
Yes. Pharmicell pays a dividend and the current yield is 0.39%; the last declared dividend was ₩50.00 per share, about ₹3.61. Dividends are taxed at your slab rate in India.
When does KRX trade, in Indian time?
The Korea Exchange trades 5:30 am – 12:00 pm IST in Indian time.
Do I have to declare Pharmicell shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. The holding is reported with its cost and its closing value.
Does the rupee rate affect what I make on Pharmicell?
Yes. Pharmicell is priced in KRW, so your rupee outcome combines the KRW move with the KRW/INR move between the day you remit and the day you convert back.